If you or someone you love has tried antidepressant after antidepressant without much relief, it can start to feel personal, as though the failure is somehow yours. New research suggests that for a meaningful share of people, the reason may lie in the kind of depression they have, not in anything they’ve done wrong.
Below, we’ve broken down what researchers mean by a “cognitive biotype” of depression, in plain language, and why it matters for how treatment is chosen.
What researchers found
Depression is often treated as a single condition, but it doesn’t look the same in everyone. Stanford researchers have described a subtype they call a “cognitive biotype,” characterized less by low mood alone and more by difficulties with the brain’s executive functions: planning, focus, decision-making, and the ability to stick with a task and filter out distractions.
Their work suggests this biotype affects a substantial portion of people with depression, and, importantly, that people in this group tend to respond less well to the antidepressants most commonly prescribed first. In other words, for these individuals, the standard medication-first approach may be less likely to work, not because the medication is bad, but because it isn’t well matched to what’s happening in the brain.
Why this matters
For a long time, finding the right depression treatment has involved a degree of trial and error, trying one medication, waiting weeks to see if it helps, then trying another. Research like this points toward a future where treatment can be matched more precisely to the individual, based on how their depression actually presents.
That’s a hopeful shift. It reframes “treatment-resistant” depression not as a dead end, but as a signal that a different approach may be needed.
Where TMS fits
This is where non-medication options become part of the conversation. Transcranial magnetic stimulation (TMS) works differently from antidepressants. Rather than acting on brain chemistry throughout the body, it uses magnetic pulses to stimulate the specific brain regions involved in mood regulation. TMS has been approved by Health Canada for the treatment of depression since 2002, with high remission and response rates and next to no systemic side effects.
For someone whose depression hasn’t responded to medication, whether or not it fits this particular cognitive biotype, TMS offers an evidence-based alternative that doesn’t rely on the same mechanism. It’s one of the reasons an individualized assessment matters so much: understanding how your depression presents helps point toward the treatment most likely to help.
The honest caveats
Research into biotypes of depression is genuinely promising, but it’s still developing. This isn’t yet a routine test you can ask your doctor for, and no single study should be read as the final word. What it does do is add weight to something clinicians have long observed: depression is not one-size-fits-all, and neither should its treatment be.
We think the most useful thing a clinic can do is share this kind of research plainly, and let it inform an honest conversation, rather than overstate what’s known.
The takeaway
If antidepressants haven’t worked for you, it doesn’t mean nothing will. It may simply mean the approach needs to change. If you’re on Vancouver Island and wondering whether TMS might be a fit, the best next step is a conversation. Our team is always happy to talk through the research and what it might mean for you.
This article is for general information and is not a substitute for individual medical advice. TMS at Optimind is a physician-directed treatment; suitability is determined through individual assessment.